Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review.

ABSTRACT:

Importance

In oncology randomized clinical trials, suboptimal access to best available care at recurrence (or relapse) may affect overall survival results.

Objective

To assess the proportion and the quality of postrecurrence treatment received by patients enrolled in US Food and Drug Administration (FDA) registration trials of systemic therapy in the adjuvant or neoadjuvant setting.

Evidence review

For this systematic review, all trials leading to an FDA approval from January 2018 through May 2023 were obtained from the FDA website and drug announcements. Randomized clinical trials of an anticancer drug in the neoadjuvant or the adjuvant setting were included. Trials of supportive care treatment and treatments given in combination with radiotherapy were excluded. Info

SUBMITTER: Olivier T 

PROVIDER: S-EPMC11190827 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature